Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 5 Effect of tau, amyloid, and Lewy body pathology on cognition

From: Association of Alzheimer’s and Lewy body disease pathology with basal forebrain volume and cognitive impairment

 

Braak

Braak

+Lewy

Braak

+CERAD

Braak

+Lewy

+CERAD

CERAD

Lewy

+CERAD

Lewy

CDR SOB

1.6*1011

6.8*1010

3.7*1010

1.6*1010

152.0

24.7

0.11

MMSE

1.9*105

2.4*104

6.1*104

7793

110.4

11.8

0.14

Boston Naming

3.2*1010

4.5*109

5.8*109

7.5*108

2316

552.4

1.0

Immediate recall

1.1*1013

3.0*1012

7.2*1012

2.2*1012

4.7*105

6.5*104

0.11

Delayed recall

4.1*1014

1.2*1014

6.4*1013

1.9*1013

5469

738.3

0.12

Animals

2.8*106

4.2*105

1.2*106

1.9*105

180.7

25.0

0.11

Vegetables

1.3*106

1.1*106

2.4*105

2.1*105

27.6

8.8

0.16

TMT B-TMT A

0.15

0.09

0.04

0.02

0.37

0.18

0.50

Digit Symbol Test

17.2

2.4

2.0

0.28

0.51

0.06

0.11

  1. Bayes factors quantifying evidence in favor of H1 over H0 (BF10) from Bayesian ANCOVAs across all groups with the respective cognitive score as dependent variable and the three neuropathological staging systems (Braak stage, CERAD score, presence of Lewy body pathology) as predictors including covariates for age, sex, years of education, and time between clinical visit and autopsy
  2. MMSE, Mini Mental State Examination; SOB, sum of boxes; TMT, Trail Making Test
Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193